Head-To-Head Review: Alpha Teknova (TKNO) vs. Its Peers

Alpha Teknova (NASDAQ:TKNO) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its competitors? We will compare Alpha Teknova to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Profitability

This table compares Alpha Teknova and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
Alpha Teknova Competitors	-540.59%	-166.46%	-13.58%

Risk and Volatility

Alpha Teknova has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Alpha Teknova’s competitors have a beta of 0.93, suggesting that their average share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Alpha Teknova and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1	1	4	0	2.50
Alpha Teknova Competitors	945	3159	5471	176	2.50

Alpha Teknova currently has a consensus price target of $8.75, indicating a potential upside of 18.89%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 4.23%. Given Alpha Teknova’s higher possible upside, equities analysts plainly believe Alpha Teknova is more favorable than its competitors.

Earnings and Valuation

This table compares Alpha Teknova and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Teknova	$40.52 million	-$17.26 million	-23.74
Alpha Teknova Competitors	$2.28 billion	$55.88 billion	-13.86

Alpha Teknova’s competitors have higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alpha Teknova competitors beat Alpha Teknova on 8 of the 13 factors compared.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.